Shots:

• The EC approval is based on a P-III TERIKIDS study evaluating Aubagioin vs PBO in 166 pediatric patients aged 10-17yrs. with RRMS across 22 countries globally- where a screening period (4wks.) is followed by a double-blind treatment period for ~96wks.
• The 1EPs is not significant with numerically a lower risk (-34%) of clinical relapse (75.3 vs 39.1wks.)- switches were more frequent (14% vs 26%). In the pre-specified sensitivity analysis- teriflunomide reduced the time to clinical relapse or switch due to high MRI activity by 43% (72.1 vs 37.0 wks.)
• Aubagio is approved in 80+ countries for RRMS with additional marketing applications under review by regulatory authorities globally

  | Ref: GlobeNewswire | Image: Pharmaceutical Technology